Edith Szafer‐Glusman

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Constantine S. Tam, John N. Allan, Tanya Siddiqi et al. · Blood · 2022 · 238 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

William G. Wierda, John N. Allan, Tanya Siddiqi et al. · Journal of Clinical Oncology · 2021 · 229 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

Marius Ilié, Edith Szafer‐Glusman, Véronique Hofman et al. · Annals of Oncology · 2017 · 202 citations · Full text

Medicine, Immunology, Oncology +17

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason et al. · Blood · 2019 · 136 citations · Full text

Medicine, Oncology, Chemotherapy +9

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klánová, Laurie H. Sehn, Isabelle Bence‐Bruckler et al. · Blood · 2019 · 129 citations · Full text

Medicine, Neurology, Oncology +11